PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

Zasocitinib NDA Acceptance: What It Means for Psoriasis Treatment

Sep 18, 2026 · 0:02:53
Listen to Episode
✨ AI Summary
  • FDA accepted NDA for zasocitinib for plaque psoriasis.
  • Investigational TYK2 inhibitor shows promise.
  • Raj Chovatiya discussed its potential treatment role.

Guests on This Episode

RC
Raj Chovatiya
researcher · 3 podcast appearances
›

More from HCPLive

HCPLive
Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites
Oct 12, 2026 · 0:03:18
HCPLive
Targeting Senescent Cells in Actinic Keratosis With RLS-1496
Oct 12, 2026 · 0:04:25
HCPLive
Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD
Oct 12, 2026 · 0:03:33
HCPLive
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
Oct 12, 2026 · 0:06:00
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →